Anti-tumor chemotherapy utilizing peptide-based approaches - Apoptotic pathways, kinases and proteasome as targets

Archivum Immunologiae et Therapiae Experimentalis

Volumn 53, Issue 1, 2005, Pages 47-60

  Mendoza, Francisco J ^a   Espino, Paula S ^a   Cann, Kendra L ^a   Bristow, Nicolle ^a   McCrea, Kristin ^a   Los, Marek ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Angiostatin; Anti angiogenic; Bortezomib; EGFR; Endostatin; HMR1826; Integrins; MDM2; p53; Velcade

Indexed keywords

ANGIOSTATIN; ANTINEOPLASTIC AGENT; BETA DEXTRO GLUCOSYLISOPHOSPHORAMIDE MUSTARD; BORTEZOMIB; CHOLECYSTOKININ OCTAPEPTIDE DERIVATIVE; CISPLATIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GLYCYLGLUTAMYLVALYLGLYCYLARGINYLGLUTAMINYLLEUCYLALANYLISOLEUCYLISOLEUCYL GLY CYLASPARTYLASPARTYLISOLEUCYLASPARAGYLARGININE; GLYCYLGLUTAMYLVALYLGLYCYLARGINYLGLUTAMYLLEUCYLALANYLISOLEUCYLISOLEUCYLGL YCY LASPARTYLASPARTYLISOLEUCYLASPARAGYLARGININE; HERBIMYCIN A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN; LYSYLLYSYLLEUCYLSERYLGLUTAMINYLCYSTEINYLLEUCYLLYSYLARGINYLISOLEUCYLGLYCY LAS PARTYLGLUTAMINYLLEUCYLASPARTYLSERINE; MITOGEN ACTIVATED PROTEIN KINASE; N (4 BETA GLUCURONYL 3 NITROBENZYLOXYCARBONYL)DOXORUBICIN; PACLITAXEL; PEPTIDE; PHOSPHOTRANSFERASE; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BCL 2; PROTEIN MDM2; PROTEIN P53; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; SERYLTHREONYLLYSYLLYSYLLEUCYLSERYLGLUTAMINYLCYSTEINYLLEUCYLLYSYLARGINYLI SOL EUCYLGLYCYLASPARTYLLEUCYLASPARTYLSERYLASPARAGYLMETHIONINE; TRASTUZUMAB; TRYPTOPHYLTHREONYLGLYCYLTRYPTOPHYLCYSTEINYLLEUCYLASPARAGYLPROLYLGLUTAMIN YLG LUTAMINYLSERYLTHREONYLTRYPTOPHYLGLYCYLPHENYLALANYLCYSTEINYLTHREONYLGLYCYLSERYLPH ENYLALANINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLGLUTAMYLARGINYLLYSYLARGINYLGLUTAMYLLYSYLLEUCYLMETHIONYLPROLINAMIDE;

ANEMIA; APOPTOSIS; ARTHRALGIA; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; FATIGUE; FEVER; GENE MUTATION; HEADACHE; HUMAN; HYPOKALEMIA; HYPONATREMIA; LUNG CANCER; NEUTROPENIA; PROTEIN PHOSPHORYLATION; PROTEIN TARGETING; REVIEW; SENSORY NEUROPATHY; TUMOR GROWTH;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; ENZYME INHIBITORS; HUMANS; INFLAMMATION; NEOPLASMS; PEPTIDES; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 14944340997     PISSN: 0004069X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (121)

1. Adams J. (2004): The proteasome: a suitable antineoplastic target. Nat. Rev. Cancer, 4, 349-360.
2. Adams J. and Kauffman M. (2004): Development of the proteasome inhibitor Velcade (Bortezomib). Cancer Invest., 22, 304-311.
3. An P., Lei H., Zhang J., Song S., He L., Jin G., Liu X., Wu J., Meng L., Liu M. and Shou C. (2004): Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int. J. Cancer, 111, 165-173.
4. Aumailley M., Gurrath M., Muller G., Calvete J., Timpl R. and Kessler H. (1991): Arg-Gly-Asp constrained within cyclic pentapeptides. Strong and selective inhibitors of cell adhesion to vitronectin and laminin fragment P1. FEBS Lett., 291, 50-54.
5. Balkwill F. and Coussens L. M. (2004): Cancer; an inflammatory link. Nature, 431, 405-406.
6. Renz A., Burek C., Mier W., Mozoluk M., Schulze-Osthoff K. and Los M. (2001): Cytochrome c is rapidly extruded from apoptotic cells and detectable in serum of anticancer-drug treated tumor patients. Adv Exp Med Biol., 495, 331-334.
7. Barr R. K., Boehm I., Attwood P. V., Watt P. M. and Bogoyevitch M. A. (2004): The critical features and the mechanism of inhibition of a kinase interaction motif-based peptide inhibitor of JNK. J. Biol. Chem., 279, 36327-36338.
8. Barr R. K., Kendrick T. S. and Bogoyevitch M. A. (2002): Identification of the critical features of a small peptide inhibitor of JNK activity. J. Biol. Chem., 277, 10987-10997.
9. Baust H., Schoke A., Brey A., Gern U., Los M., Schmid R. M., Rottinger E. M. and Seufferlein T. (2003): Evidence for radiosensitizing by gliotoxin in HL-60 cells: implications for a role of NF-κB independent mechanisms. Oncogene, 22, 8786-8796.
10. Bleasdale J. E., Ogg D., Palazuk B. J., Jacob C. S., Swanson M. L., Wang X. Y., Thompson D. P., Conradi R. A., Mathews W. R., Laborde A. L., Stuchly C. W., Heijbel A., Bergdahl K., Bannow C. A., Smith C. W., Svensson C., Liljebris C., Schostarez H. J., May P. D., Stevens F. C. and Larsen S. D. (2001): Small molecule peptidomimetics containing a novel phosphotyrosine bioisostere inhibit protein tyrosine phosphatase 1B and augment insulin action. Biochemistry, 40, 5642-5654.
11. Bonny C., Oberson A., Negri S., Sauser C. and Schorderet D. F. (2001): Cell-permeable peptide inhibitors of JNK: novel blockers of β-cell death. Diabetes, 50, 77-82.
12. Brewis N. D., Phelan A., Normand N., Choolun E. and O'Hare P. (2003): Particle assembly incorporating a VP22-BH3 fusion protein, facilitating intracellular delivery, regulated release, and apoptosis. Mol. Ther., 7, 262-270.
13. Brignole C., Pagnan G., Marimpietri D., Cosimo E., Allen T. M., Ponzoni M. and Pastorino F. (2003): Targeted delivery system for antisense oligonucleotides: a novel experimental strategy for neuroblastoma treatment. Cancer Lett., 197, 231-235.
14. Brooks P. C., Montgomery A. M., Rosenfeld M., Reisfeld R. A., Hu T., Klier G., Cheresh D. A. (1994): Integrin αvβ3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell, 79, 1157-1164.
15. Brown J. G. and Gibson S. B. (2004): Growth factors, receptors, and kinases: their exploration to target cancer. In Los M. and Gibson S. B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases. Kluwer Academic Press, New York, 173-195.
16. Buerger C., Nagel-Wolfrum K., Kunz C., Wittig I., Butz K., Hoppe-Seyler F. and Groner B. (2003): Sequence-specific peptide aptamers, interacting with the intracellular domain of the epidermal growth factor receptor, interfere with Stat3 activation and inhibit the growth of tumor cells. J. Biol. Chem., 278, 37610-37621.
17. Burek C. J., Burek M., Roth J., Los M. (2003): Calcium induces apoptosis and necrosis in hematopoietic malignant cells: evidence for caspase-8 dependent and FADD-autonomous pathway. Gene Ther. Mol. Biol., 7, 173-179.
18. Burke T. R. Jr., Yao Z. J., Liu D. G., Voigt J. and Gao Y. (2001): Phosphoryltyrosyl mimetics in the design of peptide-based signal transduction inhibitors. Biopolymers, 60, 32-44.
19. Burke T. R. Jr. and Zhang Z. Y. (1998): Protein-tyrosine phosphatases: structure, mechanism, and inhibitor discovery. Biopolymers, 47, 225-241.
20. Carmeliet P. and Jain R. K. (2000): Angiogenesis in cancer and other diseases. Nature, 407, 249-257.
21. Carroll M., Ohno-Jones S., Tamura S., Buchdunger E., Zimmermann J., Lydon N. B., Gilliland D. G. and Druker B. J. (1997): CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins. Blood, 90, 4947-4952.
22. Cassens U., Lewinski G., Samraj A. K., von Bernuth H., Baust H., Khazaie K. and Los M. (2003): Viral modulation of cell death by inhibition of caspases. Arch. Immunol. Ther. Exp., 51, 19-27.
23. Chai J., Du C., Wu J. W., Kyin S., Wang X. and Shi Y. (2000): Structural and biochemical basis of apoptotic activation by Smac/DIABLO. Nature, 406, 855-862.
24. Chauhan D., Li G., Podar K., Hideshima T., Shringarpure R., Catley L., Mitsiades C., Munshi N., Tai Y. T., Suh N., Gribble G. W., Honda T., Schlossman R., Richardson P., Sporn M. B. and Anderson K. C. (2004): The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood, 103, 3158-3166.
25. Cherlonneix L. (2004): From life without death to permanent delaying of death in life (De la vie sans mort à la Vie en suspens). Rev. Hist. Épistémolog. Sci. Vie, 11, 139-161.
26. Cosulich S. C., Worrall V., Hedge P. J., Green S. and Clarke P. R. (1997): Regulation of apoptosis by BH3 domains in a cell-free system. Curr. Biol., 7, 913-920.
27. Dai Y., Rahmani M. and Grant S. (2003): Proteasome inhibitors potentiate leukemic cell apoptosis induced by the cyclin-dependent kinase inhibitor flavopiridol through a SAPK/JNK- and NF-κB-dependent process. Oncogene, 22, 7108-2122.
28. Danial N. N. and Korsmeyer S. J. (2004): Cell death: critical control points. Cell, 116, 205-219.
29. Denlinger C. E., Keller M. D., Mayo M. W., Broad R. M. and Jones D. R. (2004): Combined proteasome and histone deacetylase inhibition in non-small cell lung cancer. J. Thorac. Cardiovasc. Surg., 127, 1078-1086.
30. Do T. N., Rosal R. V., Drew L., Raffo A. J., Michl J., Pincus M. R., Friedman F. K., Petrylak D. P., Cassai N., Szmulewicz J., Sidhu G., Fine R. L. and Brandt-Rauf P. W. (2003): Preferential induction of necrosis in human breast cancer cells by a p53 peptide derived from the MDM2 binding site. Oncogene, 22, 1431-1444.
31. Dubowchik G. M. and Walker M. A. (1999): Receptor-mediated and enzyme-dependent targeting of cytotoxic anticancer drugs. Pharmacol. Ther., 83, 67-123.
32. Ellis L. M. (2003): Antiangiogenic therapy: more promise and, yet again, more questions. J. Clin. Oncol., 21, 3897-3899.
33. Ellis L. M. (2003): A targeted approach for antiangiogenic therapy of metastatic human colon cancer. Am. Surg., 69, 3-10.
34. Erez N., Zamir E., Gour B. J., Blaschuk O. W. and Geiger B. (2004): Induction of apoptosis in cultured endothelial cells by a cadherin antagonist peptide: involvement of fibroblast growth factor receptor-mediated signalling. Exp. Cell Res., 294, 366-378.
35. Ernst J. T., Becerril J., Park H. S., Yin H. and Hamilton A. D. (2003): Design and application of an α-helix-mimetic scaffold based on an oligoamide-foldamer strategy: antagonism of the Bak BH3/Bcl-xL complex. Angew. Chem. Int. Ed. Engl., 42, 535-539.
36. Everett H. and McFadden G. (2002): Poxviruses and apoptosis: a time to die. Curr. Opin. Microbiol., 5, 395-402.
37. Finlan L. E. and Hupp T. R. (2004): The life cycle of p53: a key target in drug development. In Los M. and Gibson S. B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases. Kluwer Academic Press, New York, 157-172.
38. Folkman J. (1995): Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N. Engl. J. Med., 333, 1757-1763.
39. Folkman J. (1996): Fighting cancer by attacking its blood supply. Sci. Am., 275, 150-154.
40. Folkman J. (2002): Role of angiogenesis in tumor growth and metastasis. Semin. Oncol., 29, 15-18.
41. Friedler A., DeDecker B. S., Freund S. M., Blair C., Rudiger S. and Fersht A. R. (2004): Structural distortion of p53 by the mutation R249S and its rescue by a designed peptide: implications for "mutant conformation". J. Mol. Biol., 336, 187-196.
42. Friedler A., Hansson L. O., Veprintsev D. B., Freund S. M., Rippin T. M., Nikolova P. V., Proctor M. R., Rudiger S. and Fersht A. R. (2002): A peptide that binds and stabilizes p53 core domain: chaperone strategy for rescue of oncogenic mutants. Proc. Natl. Acad. Sci. USA, 99, 937-942.
43. Frixen U. H., Behrens J., Sachs M., Eberle G., Voss B., Warda A., Lochner D. and Birchmeier W. (1991): E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells. J. Cell Biol., 113, 173-185.
44. Fulda S., Wick W., Weller M. and Debatin K. M. (2002): Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat. Med., 8, 808-815.
45. Ghavami S., Kerkhoff C., Los M., Hashemi M., Sorg C. and Karami-Tehrani F. (2004): Mechanism of apoptosis induced by S100A8/A9 in colon cancer cell lines: the role of ROS and the effect of metal ions. J. Leukoc. Biol., 76, 169-175.
46. Goy A. and Gilles F. (2004): Update on the proteasome inhibitor bortezomib in hematologic malignancies. Clin. Lymphoma. 4. 230-237.
47. Grotzinger C. and Wiedenmann B. (2004): Somatostatin receptor targeting for tumor imaging and therapy. Ann. NY Acad. Sci., 1014, 258-264.
48. Guo F., Nimmanapalli R., Paranawithana S., Wittman S., Griffin D., Bali P., O'Bryan E., Fumero C., Wang H. G. and Bhalla K. (2002): Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/DIABLO) or cotreatment with N-terminus of Smac/DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood, 99, 3419-3426.
49. Hackam D. G. and Kapral M. K. (2004): Progress in clinical neurosciences: pharmacotherapies for the secondary prevention of stroke. Can. J. Neurol. Sci., 31, 295-303.
50. Hainaut P. and Hollstein M. (2000): p53 and human cancer: the first ten thousand mutations. Adv. Cancer Res., 77, 81-137.
51. Hammes H. P., Brownlee M., Jonczyk A., Sutter A. and Preissner K. T. (1996): Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med., 2, 529-233.
52. Haubner R. and Wester H. J. (2004): Radiolabeled tracers for imaging of tumor angiogenesis and evaluation of anti-angiogenic therapies. Curr. Pharm. Des., 10, 1439-1455.
53. Haupt Y., Maya R., Kazaz A. and Oren M. (1997): Mdm2 promotes the rapid degradation of p53. Nature, 387, 296-299.
54. Holinger E. P., Chittenden T. and Lutz R. J. (1999): Bak BH3 peptides antagonize Bcl-xL function and induce apoptosis through cytochrome c-independent activation of caspases. J. Biol. Chem., 274, 13298-13304.
55. Houshmand P. and Zlotnik A. (2003): Targeting tumor cells. Curr. Opin. Cell Biol., 15, 640-644.
56. Huang P. S. and Oliff A. (2001): Drug-targeting strategies in cancer therapy. Curr. Opin. Genet. Dev., 11, 104-110.
57. Huang Z. (2000): Bcl-2 family proteins as targets for anticancer drug design. Oncogene, 19, 6627-6631.
58. Huang Z. (2002): The chemical biology of apoptosis. Exploring protein-protein interactions and the life and death of cells with small molecules. Chem. Biol., 9, 1059-1072.
59. Ikezoe T., Yang Y., Saito T., Koeffler H. P. and Taguchi H. (2004): Proteasome inhibitor PS-341 down-regulates prostate-specific antigen (PSA) and induces growth arrest and apoptosis of androgen-dependent human prostate cancer LNCaP cells. Cancer Sci., 95, 271-275.
60. Issaeva N., Friedler A., Bozko P., Wiman K. G., Fersht A. R. and Selivanova G. (2003): Rescue of mutants of the tumor suppressor p53 in cancer cells by a designed peptide. Proc. Natl. Acad. Sci. USA, 100, 13303-13307.
61. Johar D., Roth J. C., Bay G. H., Walker J. N., Rroczak T. J. and Los M. (2004): Inflammatory response, reactive oxygen species, programmed (necrotic-like and apoptotic) cell death and cancer. Rocz. Akad. Med. Bialymst., 49, 31-39.
62. Jothy S., Munro S. B., LeDuy L., McClure D. and Blaschuk O. W. (1995): Adhesion or anti-adhesion in cancer: what matters more? Cancer Metastasis Rev., 14, 363-376.
63. Kabore A. F., Johnston J. B. and Gibson S. B. (2004): Changes in the apoptotic and survival signaling in cancer cells and their potential therapeutic implications. Curr. Cancer Drug Targets, 4, 147-163.
64. Kamath J. R., Liu R., Enstrom A. M., Lou Q. and Lam K. S. (2003): Development and characterization of potent and specific peptide inhibitors of p60c-src protein tyrosine kinase using pseudosubstrate-based inhibitor design approach. J. Pept. Res., 62, 260-268.
65. Kanovsky M., Raffo A., Drew L., Rosal R., Do T., Friedman F. K., Rubinstein P., Visser J., Robinson R., Brandt-Rauf P. W., Michl J., Fine R. L. and Pincus M. R. (2001): Peptides from the amino terminal mdm-2-binding domain of p53, designed from conformational analysis, are selectively cytotoxic to transformed cells. Proc. Natl. Acad. Sci. USA, 98, 12438-12443.
66. Kawanishi S. and Hiraku Y. (2004): Amplification of anticancer drug-induced DNA damage and apoptosis by DNA-binding compounds. Curr. Med. Chem. Anti-Cane. Agents, 4, 415-419.
67. Kim A. L., Raffo A. J., Brandt-Rauf P. W., Pincus M. R., Monaco R., Abarzua P. and Fine R. L. (1999): Conformational and molecular basis for induction of apoptosis by a p53 C-terminal peptide in human cancer cells. J. Biol. Chem., 274, 34924-34931.
68. Kreuter M., Langer C., Kerkhoff C., Reddanna P., Kania A. L., Maddika S., Chlichlia K., Bui T. N. and Los M. (2004): Stroke, myocardial infarction, acute and chronic inflammatory diseases: caspases and other apoptotic molecules as targets for drug development. Arch. Immunol. Ther. Exp., 52, 141-155.
69. Kritzer J. A., Lear J. D., Hodsdon M. E. and Schepartz A. (2004): Helical β-peptide inhibitors of the p53-hDM2 interaction. J. Am. Chem. Soc., 126, 9468-9469.
70. Kutzki O., Park H. S., Ernst J. T., Orner B. P., Yin H. and Hamilton A. D. (2002): Development of a potent Bcl-x(L) antagonist based on alpha-helix mimicry. J. Am. Chem. Soc., 124, 11838-11839.
71. Lara P. N., Jr., Davies A. M., Mack P. C., Mortenson M. M., Bold R. J., Gumerlock P. H. and Gandara D. R. (2004): Proteasome inhibition with PS-341 (bortezomib) in lung cancer therapy. Semin. Oncol., 31, 40-46.
72. Letai A., Bassik M. C., Walensky L. D., Sorcinelli M. D., Weiler S. and Korsmeyer S. J. (2002): Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell, 2, 183-192.
73. Li P., Zhang M., Peach M. L., Liu H., Yang D. and Roller P. P. (2003): Concise and enantioselective synthesis of Fmoc-Pmp(But)2-OH and design of potent Pmp-containing Grb2-SH2 domain antagonists. Org. Lett., 5, 3095-3098.
74. Liljebris C., Larsen S. D., Ogg D., Palazuk B. J. and Bleasdale J. E. (2002): Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity. J. Med. Chem., 45, 1785-1798.
75. Liu D. and Huang Z. (2001): Synthetic peptides and non-peptidic molecules as probes of structure and function of Bcl-2 family proteins and modulators of apoptosis. Apoptosis, 6, 453-462.
76. Liu Z., Sun C., Olejniczak E. T., Meadows R. P., Betz S. F., Oost T., Herrmann J., Wu J. C. and Fesik S. W. (2000): Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain. Nature. 408, 1004-1008.
77. Lochmann D., Jauk E. and Zimmer A. (2004): Drug delivery of oligonucleotides by peptides. Eur. J. Pharm. Biopharm., 58, 237-251.
78. Los M., Burek C. J., Stroh C., Benedyk K., Hug H. and Mackiewicz A. (2003): Anticancer drugs of tomorrow: apoptotic pathways as targets for drug design. Drug Discov. Today, 8, 67-77.
79. Los M., Mozoluk M., Ferrari D., Stepczynska A., Stroh C., Renz A., Herceg Z., Wang Z.-Q. and Schulze-Osthoff K. (2002):. Activation and caspase-mediated inhibition of PARP: a molecular switch between fibroblast necrosis and apoptosis in death receptor signaling. Mol. Biol. Cell, 13, 978-988.
80. Lysik M. A. and Wu-Pong S. (2003): Innovations in oligonucleotide drug delivery. J. Pharm. Sci., 92, 1559-1573.
81. Manion M. K. and Hockenbery D. M. (2003): Targeting BCL-2-related proteins in cancer therapy. Cancer Biol. Ther., 2, S105-114.
82. Mareel M., Vleminckx K., Vermeulen S., Bracke M. and Van Roy F. (1992): E-cadherin expression: a counterbalance for cancer cell invasion. Bull. Cancer, 79, 347-355.
83. Masdehors P., Merle-Beral H., Maloum K., Omura S., Magdelenat H. and Delic J. (2000): Deregulation of the ubiquitin system and p53 proteolysis modify the apoptotic response in B-CLL lymphocytes. Blood, 96, 269-274.
84. Mazitschek R., Baumhof P. and Giannis A. (2002): Peptido-mimetics and angiogenesis. Mini Rev. Med. Chem., 2, 491-506.
85. Mier W., Hoffend J., Haberkorn U. and Eisenhut M. (2004): Current strategies in tumor-targeting. In Los M. and Gibson S.B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases. Kluwer Academic Press, New York, 345-356.
86. Narita M., Shimizu S., Ito T., Chittenden T., Lutz R. J., Matsuda H. and Tsujimoto Y. (1998): Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria. Proc Natl Acad Sci USA, 95, 14681-14686.
87. Nimmanapalli R. and Bhalla K. (2003): Targets in apoptosis signaling: promise of selective anticancer therapy. Methods Mol. Biol., 223, 465-483.
88. O'Reilly M. S., Boehm T., Shing Y., Fukai N., Vasios G., Lane W. S., Flynn E., Birkhead J. R., Olsen B. R. and Folkman J. (1997): Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell, 88, 277-285.
89. O'Reilly M. S., Holmgren L., Chen C. and Folkman J. (1996): Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat. Med., 2, 689-692.
90. Orlowski R. (2004): Targeting the proteosome in cancer therapy. In Los M. and Gibson S. B. (eds.): Apoptotic pathways as target for novel therapies in cancer and other diseases. Kluwer Academic Press, New York, 243-274.
91. Papandreou C. N., Daliani D. D., Nix D., Yang H., Madden T., Wang X., Pien C. S., Millikan R. E., Tu S. M., Pagliaro L., Kim J., Adams J., Elliott P., Esseltine D., Petrusich A., Dieringer P., Perez C. and Logothetis C. J. (2004): Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer. J. Clin. Oncol., 22, 2108-2121.
92. Pero S. C., Shukla G. S., Armstrong A. L., Peterson D., Fuller S. P., Godin K., Kingsley-Richards S. L., Weaver D. L., Bond J. and Krag D. N. (2004): Identification of a small peptide that inhibits the phosphorylation of ErbB2 and proliferation of ErbB2 overexpressing breast cancer cells. Int. J. Cancer, 111, 951-960.
93. Petros A. M., Nettesheim D. G., Wang Y., Olejniczak E. T., Meadows R. P., Mack J., Swift K., Matayoshi E. D., Zhang H., Thompson C. B. and Fesik S. W. (2000): Rationale for Bcl-xL/Bad peptide complex formation from structure, mutagenesis, and biophysical studies. Protein Sci., 9, 2528-2534.
94. Philchenkov A., Zavelevich M., Kroczak T. J. and Los M. (2004): Caspases and cancer: mechanisms of inactivation and new treatment modalities. Exp. Oncol., 26, 82-97.
95. Ragin A. D., Morgan R. A. and Chmielewski J. (2002): Cellular import mediated by nuclear localization signal peptide sequences. Chem. Biol., 9, 943-948.
96. Renz A., Berdel W. E., Kreuter M., Belka C., Schulze-Osthoff K. and Los M. (2001): Rapid extracellular release of cytochrome c is specific for apoptosis and marks cell death in vivo. Blood, 98, 1542-1548.
97. Richard J. P., Melikov K., Vives E., Ramos C., Verbeure B., Gait M. J., Chernomordik L. V. and Lebleu B. (2003): Cell-penetrating peptides. A reevaluation of the mechanism of cellular uptake. J. Biol. Chem., 278, 585-590.
98. Romanov V. I. (2003): Phage display selection and evaluation of cancer drug targets. Curr. Cancer Drug Targets, 3, 119-129.
99. Rosal R., Pincus M. R., Brandt-Rauf P. W., Fine R. L., Michl J. and Wang H. (2004): NMR solution structure of a peptide from the mdm-2 binding domain of the p53 protein that is selectively cytotoxic to cancer cells. Biochemistry, 43, 1854-1861.
100. Sawyer T. K. (1998): Src homology-2 domains: structure, mechanisms, and drug discovery. Biopolymers, 47, 243-261.
101. Schipper J. H., Frixen U. H., Behrens J., Unger A., Jahnke K. and Birchmeier W. (1991): E-cadherin expression in squamous cell carcinomas of head and neck: inverse correlation with tumor dedifferentiation and lymph node metastasis. Cancer Res., 51, 6328-6337.
102. Selivanova G., Iotsova V., Okan I., Fritsche M., Strom M., Groner B., Grafstrom R. C. and Wiman K. G. (1997): Restoration of the growth suppression function of mutant p53 by a synthetic peptide derived from the p53 C-terminal domain. Nat. Med., 3, 632-638.
103. Selivanova G., Ryabchenko L., Jansson E., Iotsova V. and Wiman K. G. (1999): Reactivation of mutant p53 through interaction of a C-terminal peptide with the core domain. Mol. Cell Biol., 19, 3395-3402.
104. Shadidi M. and Sioud M. (2003): Identification of novel carrier peptides for the specific delivery of therapeutics into cancer cells. FASEB J., 17, 256-258.
105. Shadidi M. and Sioud M. (2003): Selective targeting of cancer cells using synthetic peptides. Drug Resist. Updat, 6, 363-371.
106. Shugar D. (1995): Protein kinase inhibitors-potential chemotherapeutic agents. Acta Biochim. Pol., 42, 405-418.
107. Thompson C. B. (1995): Apoptosis in the pathogenesis and treatment of disease. Science, 267, 1456-1462.
108. van Dijk M. A. and van de Winkel J. G. (2001): Human antibodies as next generation therapeutics. Curr. Opin. Chem. Biol., 5, 368-374.
109. +-D-glucose cotransporter SAAT1. Proc. Natl. Acad. Sci. USA, 95, 2914-2919.
110. Vleminckx K., Vakaet L. Jr., Mareel M., Fiers W. and van Roy F. (1991): Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. Cell, 66, 107-119:
111. Walensky L. D., Kung A. L., Escher I., Malia T. J., Barbuto S., Wright R. D., Wagner G., Verdine G. L. and Korsmeyer S. J. (2004): Activation of apoptosis in vivo by a hydrocarbon-stapled BH3 helix. Science, 305, 1466-1470.
112. Walsh M., Lutz R. J., Cotter T. G. and O'Connor R. (2002): Erythrocyte survival is promoted by plasma and suppressed by a Bak-derived BH3 peptide that interacts with membrane-associated Bcl-X(L). Blood, 99, 3439-3448.
113. Wang J. L., Zhang Z. J., Choksi S., Shan S., Lu Z., Croce C. M., Alnemri E. S., Korngold R. and Huang Z. (2000): Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res., 60, 1498-1502.
114. Wang W., Rastinejad F. and El-Deiry W. S. (2003): Restoring p53-dependent tumor suppression. Cancer Biol. Ther., 2, S55-63.
115. Welz C., Neuhuber W., Schreier H., Metzler M., Repp R., Rascher W. and Fahr A. (2000): Nuclear transport of oligonucleotides in HepG2-cells mediated by protamine sulfate and negatively charged liposomes. Pharm. Res., 17, 1206-1211.
116. Wu G., Chai J., Suber T. L., Wu J. W., Du C., Wang X. and Shi Y. (2000): Structural basis of IAP recognition by Smac/DIABLO. Nature, 408, 1008-1012.
117. Yang B., Liu D. and Huang Z. (2004): Synthesis and helical structure of lactam bridged BH3 peptides derived from pro-apoptotic Bcl-2 family proteins. Bioorg. Med. Chem. Lett., 14, 1403-1406.
118. Yang L., Mashima T., Sato S., Mochizuki M., Sakamoto H., Yamori T., Oh-Hara T. and Tsuruo T. (2003): Predominant suppression of apoptosome by inhibitor of apoptosis protein in non-small cell lung cancer H460 cells: therapeutic effect of a novel polyarginine-conjugated Smac peptide. Cancer Res., 63, 831-837.
119. Yang Y., Ikezoe T., Saito T., Kobayashi M., Koeffler H. P. and Taguchi H. (2004): Proteasome inhibitor PS-341 induces growth arrest and apoptosis of non-small cell lung cancer cells via the JNK/c-Jun/AP-1 signaling. Cancer Sci., 95, 176-180.
120. Yin H. and Hamilton A. D. (2004): Terephthalamide derivatives as mimetics of the helical region of Bak peptide target Bcl-xL protein. Bioorg. Med. Chem. Lett., 14, 1375-1379.
121. Yokoyama Y. and Ramakrishnan S. (2004): Addition of integrin binding sequence to a mutant human endostatin improves inhibition of tumor growth. Int. J. Cancer, 111, 839-848.